Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax
- Country:
- Russia
Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.
Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Russian
- Interfax
- CanSino Biologics
- Chinese
Advertisement
ALSO READ
Russian forces enter suburb of Chasiv Yar in Ukraine, says RIA
Ukrainian military denies Russian forces have reached suburbs of Chasiv Yar
Russian rouble slightly weaker against the US dollar
Russian overnight drone attack damages energy infrastructure in Odesa region
Russian military says it took control of village in eastern Ukraine
Google News